Evaluation of Promoter hyper methylation of DNMTA3 and DNMT3B enzymes in endometrial carcinoma patients

Endometrial cancer is a major threat for woman health in the world. Development in our ability for diagnosis, prevention and treatment of the disease required more understanding about genetic and epigenetic basis of endometrial carcinogenesis. Our purpose was analysis of promoter methylation of enzymes, DNMT3a and DNMT3b, involved in de novo methylation in endometrial carcinogenesis. Genomic DNA was extracted from blood samples of 26 patients and 28 tissues simultaneously. In this study MSP technique (methylation specific PCR) which is a qualitative method was used to determine methylation patterns. Amplification was performed using specific primers for methylated and un-methylated DNA. Results were analyzed by electrophoresis on agarose gel. Finally statistic data was analyzed by chi-Square test. Our results indicated methylation status between tissue and blood samples of DNMT3A, gene was not significant (p=0.79). Also correlation between menosososal state with DNMT3B promoter methylation was observed (P=0.06). But no significant relationship was found between methylation of DNMT3A and DNMT3B genes and parameters such as: tumor grade or type. In our study Hypermethylation of studied genes suggested as an important event in carcinogenesis of endometrial cancer. Epigenetic alternations may have diagnostic value for early detection and better clinical management of susceptibility to endometrial malignancies. Also detection of methylated genes in blood samples could lead to the development of a screening test to non-invasively identify early cancer in high-risk people.